Live-attenuated bacterial vectors: Tools for vaccine and therapeutic agent delivery

Vaccines

Volumn 3, Issue 4, 2015, Pages 940-972

  Lin, Ivan Y C ^a   Van, Thi Thu Hao ^a   Smooker, Peter M ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Attenuated vector; Cancer therapy; Infectious disease; Salmonella; Vaccine

Indexed keywords

BACTERIAL VECTOR; CD24 ANTIGEN; CYCLIC AMP; CYTOSINE DEAMINASE; ENDOSTATIN; FLUCYTOSINE; GAMMA INTERFERON; GANCICLOVIR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN C; TUMOR ANTIGEN; VACCINE;

ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM ATTENUATION; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL (TOPIC); DNA TRANSFER; DRUG DELIVERY SYSTEM; GENE MUTATION; GENETIC STABILITY; HUMAN; IMMUNOGENICITY; INFECTION; LISTERIA MONOCYTOGENES; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SALMONELLA; SALMONELLA ENTERICA; STAPHYLOCOCCUS; TUMOR MICROENVIRONMENT; VACCINATION; VIBRIO CHOLERAE;

EID: 85016892168     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3040940     Document Type: Review

References (197)

1. Shata, M.T.; Stevceva, L.; Agwale, S.; Lewis, G.K.; Hone, D.M. Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today 2000, 6, 66-71.
2. Carleton, H.A. Pathogenic bacteria as vaccine vectors: Teaching old bugs new tricks. Yale J. Biol. Med. 2010, 83, 217-222.
3. Van, T.T.H.; Lin, Y.-C.; Van, T.N.N.; Nguyen, T.Q.; Le, T.T.H.; Do, T.H.; Truong, N.H.; Coloe, P.J.; Smooker, P.M. Salmonella as a vaccine vector for influenza virus. Procedia Vaccinol. 2013, 7, 23-27.
4. Goya, A.K.; Khatri, K.; Mishra, N.; Vyas, S.P. New patents on mucosal delivery of vaccines. Expert Opin. Ther. Pat. 2008, 18, 1271-1288.
5. Hone, D.M.; Harris, A.M.; Chatfield, S.; Dougan, G.; Levine, M.M. Construction of genetically defined double aro mutants of Salmonella Typhi. Vaccine 1991, 9, 810-816.
6. Strahan, K.; Chatfield, S.N.; Tite, J.; Dougan, G.; Hormaeche, C.E. Impaired resistance to infection does not increase the virulence of Salmonella htrA live vaccines for mice. Microb. Pathog. 1992, 12, 311-317.
7. Kotloff, K.L.; Noriega, F.; Losonsky, G.A.; Sztein, M.B.; Wasserman, S.S.; Nataro, J.P.; Levine, M.M. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun. 1996, 64, 4542-4548.
8. van Loon, F.P.; Clemens, J.D.; Chakraborty, J.; Rao, M.R.; Kay, B.A.; Sack, D.A.; Yunus, M.; Ali, M.; Svennerholm, A.M.; Holmgren, J. Field trial of inactivated oral cholera vaccines in Bangladesh: Results from 5 years of follow-up. Vaccine 1996, 14, 162-166.
9. Olanratmanee, T.; Levine, M.; Losonsky, G.; Thisyakorn, U.; Cryz, S., Jr. Safety and immunogenicity of Salmonella Typhi Ty21a liquid formulation vaccine in 4 to 6 year old Thai children. J. Infect. Dis. 1992, 166, 451-452.
10. Mouricout, M. Interactions between the enteric pathogen and the host. An assortment of bacterial lectins and a set of glycoconjugate receptors. Adv. Exp. Med. Biol. 1997, 412, 109-123.
11. Leclerc, C. New technologies for vaccine development. Med. Sci. (Paris) 2007, 23, 386-390.
12. Gerdts, V.; Mutwiri, G.K.; Tikoo, S.K.; Babiuk, L.A. Mucosal delivery of vaccines in domestic animals. Vet. Res. 2006, 37, 487-510.
13. Chinchilla, M.; Pasetti, M.F.; Medina-Moreno, S.; Wang, J.Y.; Gomez-Duarte, O.G.; Stout, R.; Levine, M.M.; Galen, J.E. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect. Immun. 2007, 75, 3769-3779.
14. Saxena, M.; Van, T.T.H.; Baird, F.J.; Coloe, P.J.; Smooker, P.M. Pre-existing immunity against vaccine vectors--Friend or foe? Microbiology 2013, 159, 1-11.
15. Germanier, R.; Furer, E. Isolation and characterization of Gal E mutant Ty21a of Salmonella Typhi - candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 1975, 131, 553-558.
16. Oettinger, T.; Jorgensen, M.; Ladefoged, A.; Haslov, K.; Andersen, P. Development of the Mycobacterium bovis BCG vaccine: Review of the historical and biochemical evidence for a genealogical tree. Tuber. Lung Dis. 1999, 79, 243-250.
17. Galan, J.E.; Curtiss, R., 3rd. Virulence and vaccine potential of phoP mutants of Salmonella Typhimurium. Microb. Pathog. 1989, 6, 433-443.
18. Coloe, P.J.; Alderton, M.R.; Gerraty, N.L.; Christopher, W.; Smith, S.C. Aromatic vitamin-dependent Salmonellae as vaccines in food animals: Efficacy and persistence. Dev. Biol. Stand. 1995, 84, 263-267.
19. Bachtiar, E.W.; Sheng, K.C.; Fifis, T.; Gamvrellis, A.; Plebanski, M.; Coloe, P.J.; Smooker, P.M. Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol. Lett. 2003, 227, 211-217.
20. Cheminay, C.; Hensel, M. Rational design of Salmonella recombinant vaccines. Int. J. Med. Microbiol. 2008, 298, 87-98.
21. Hall, L.J.; Clare, S.; Pickard, D.; Clark, S.O.; Kelly, D.L.F.; Ghany, M.A.E.; Hale, C.; Dietrich, J.; Andersen, P.; Marsh, P.D.; et al. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine 2009, 27, 6894-6904.
22. Darji, A.; Guzman, C.A.; Gerstel, B.; Wachholz, P.; Timmis, K.N.; Wehland, J.; Chakraborty, T.; Weiss, S. Oral somatic transgene vaccination using attenuated S. Typhimurium. Cell 1997, 91, 765-775.
23. Curtiss, R., 3rd; Kelly, S.M. Salmonella Typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 1987, 55, 3035-3043.
24. Hall, H.K.; Foster, J.W. The role of fur in the acid tolerance response of Salmonella Typhimurium is physiologically and genetically separable from its role in iron acquisition. J. Bacteriol. 1996, 178, 5683-5691.
25. Zhang, X.; Wanda, S.-Y.; Brenneman, K.; Kong, W.; Zhang, X.; Roland, K.; Curtiss, R. Improving Salmonella vector with rec mutation to stabilize the DNA cargoes. BMC Microbiol. 2011, doi:10.1186/1471-2180-11-31.
26. Seo, K.Y.; Han, S.J.; Cha, H.R.; Seo, S.U.; Song, J.H.; Chung, S.H.; Kweon, M.N. Eye mucosa: An efficient vaccine delivery route for inducing protective immunity. J. Immunol. 2010, 185, 3610-3619.
27. Cardenas, L.; Clements, J.D. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin. Microbiol. Rev. 1992, 5, 328-342.
28. Kotton, C.N.; Hohmann, E.L. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect. Immun. 2004, 72, 5535-5547.
29. Levine, M.M.; Tacket, C.O.; Sztein, M.B. Host-Salmonella interaction: Human trials. Microb. Infect. 2001, 3, 1271-1279.
30. McGhie, E.J.; Brawn, L.C.; Hume, P.J.; Humphreys, D.; Koronakis, V. Salmonella takes control: Effector-driven manipulation of the host. Curr. Opin. Microbiol. 2009, 12, 117-124.
31. Santos, R.L.; Tsolis, R.M.; Baumler, A.J.; Adams, L.G. Pathogenesis of Salmonella-induced enteritis. Braz. J. Med. Biol. Res. 2003, 36, 3-12.
32. Patel, J.C.; Galan, J.E. Manipulation of the host actin cytoskeleton by Salmonella-All in the name of entry. Curr. Opin. Microbiol. 2005, 8, 10-15.
33. Hohmann, E.L.; Oletta, C.A.; Miller, S.I. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella Typhi vaccine strain in human volunteers. Vaccine 1996, 14, 19-24.
34. Nardelli-Haefliger, D.; Kraehenbuhl, J.P.; Curtiss, R., 3rd; Schodel, F.; Potts, A.; Kelly, S.; de Grandi, P. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella Typhi vaccine strain. Infect. Immun. 1996, 64, 5219-5224.
35. Shi, H.; Santander, J.; Brenneman, K.E.; Wanda, S.Y.; Wang, S.; Senechal, P.; Sun, W.; Roland, K.L.; Curtiss, R. Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS ONE 2010, 5, e11142.
36. Husseiny, M.I.; Hensel, M. Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins. Vaccine 2009, 27, 3780-3787.
37. Matic, J.N.; Terry, T.D.; van Bockel, D.; Maddocks, T.; Tinworth, D.; Jennings, M.P.; Djordjevic, S.P.; Walker, M.J. Development of non-antibiotic-resistant, chromosomally based, constitutive and inducible expression systems for aroA-attenuated Salmonella enterica serovar Typhimurium. Infect. Immun. 2009, 77, 1817-1826.
38. Dunstan, S.J.; Simmons, C.P.; Strugnell, R.A. In vitro and in vivo stability of recombinant plasmids in a vaccine strain of Salmonella enterica var. Typhimurium. FEMS Immunol. Med. Microbiol. 2003, 37, 111-119.
39. Million-Weaver, S.; Camps, M. Mechanisms of plasmid segregation: Have multicopy plasmids been overlooked? Plasmid 2014, 75, 27-36.
40. Galen, J.E.; Pasetti, M.F.; Tennant, S.; Ruiz-Olvera, P.; Sztein, M.B.; Levine, M.M. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol. Cell Biol. 2009, 87, 400-412.
41. Garcillán-Barcia, M.P.; Alvarado, A.; de la Cruz, F. Identification of bacterial plasmids based on mobility and plasmid population biology. FEMS Microbiol. Rev. 2011, 35, 936-956.
42. Thomas, C.M. Paradigms of plasmid organization. Mol. Microbiol. 2000, 37, 485-491.
43. Galan, J.E.; Nakayama, K.; Curtiss, R., 3rd. Cloning and characterization of the asd gene of Salmonella Typhimurium: Use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 1990, 94, 29-35.
44. Schodel, F.; Peterson, D.; Hughes, J.; Wirtz, R.; Milich, D. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. J. Biotechnol. 1996, 44, 91-96.
45. Yang, X.; Hinnebusch, B.J.; Trunkle, T.; Bosio, C.M.; Suo, Z.; Tighe, M.; Harmsen, A.; Becker, T.; Crist, K.; Walters, N.; et al. Oral vaccination with Salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J. Immunol. 2007, 178, 1059-1067.
46. Hohmann, E.L.; Oletta, C.A.; Loomis, W.P.; Miller, S.I. Macrophage-inducible expression of a model antigen in Salmonella Typhimurium enhances immunogenicity. Proc. Natl. Acad. Sci. USA 1995, 92, 2904-2908.
47. Wang, S.; Li, Y.; Shi, H.; Sun, W.; Roland, K.L.; Curtiss, R., 3rd. Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines. Infect. Immun. 2011, 79, 937-949.
48. Christman, M.F.; Morgan, R.W.; Jacobson, F.S.; Ames, B.N. Positive control of a regulon for defenses against oxidative stress and some heat-shock proteins in Salmonella Typhimurium. Cell 1985, 41, 753-762.
49. Guan, L.; Mu, W.; Champeimont, J.; Wang, Q.; Wu, H.; Xiao, J.; Lubitz, W.; Zhang, Y.; Liu, Q. Iron-regulated lysis of recombinant Escherichia coli in host releases protective antigen and confers biological containment. Infect. Immun. 2011, 79, 2608-2618.
50. 2+ as an extracellular signal: Environmental regulation of Salmonella virulence. Cell 1996, 84, 165-174.
51. Chu, T.; Ni, C.; Zhang, L.; Wang, Q.; Xiao, J.; Zhang, Y.; Liu, Q. A quorum sensing-based in vivo expression system and its application in multivalent bacterial vaccine. Microb. Cell Fact. 2015, doi:10.1186/s12934-015-0213-9.
52. Galen, J.E.; Levine, M.M. Can a "flawless" live vector vaccine strain be engineered? Trends. Microbiol. 2001, 9, 372-376.
53. Haddad, D.; Liljeqvist, S.; Kumar, S.; Hansson, M.; Stahl, S.; Perlmann, H.; Perlmann, P.; Berzins, K. Surface display compared to periplasmic expression of a malarial antigen in Salmonella Typhimurium and its implications for immunogenicity. FEMS Immunol. Med. Microbiol. 1995, 12, 175-186.
54. Kang, H.Y.; Curtiss, R., 3rd. Immune responses dependent on antigen location in recombinant attenuated Salmonella Typhimurium vaccines following oral immunization. FEMS Immunol. Med. Microbiol. 2003, 37, 99-104.
55. Hobom, G.; Arnold, N.; Ruppert, A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane. Dev. Biol. Stand. 1995, 84, 255-262.
56. Charbit, A. Maltodextrin transport through lamB. Front. Biosci. 2003, 8, s265-s274.
57. Kajikawa, A.; Igimi, S. Innate and acquired immune responses induced by recombinant Lactobacillus casei displaying flagellin-fusion antigen on the cell-surface. Vaccine 2010, 28, 3409-3415.
58. Shahabi, V.; Maciag, P.C.; Rivera, S.; Wallecha, A. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng. Bugs 2010, 1, 235-239.
59. Lewis, G.K. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: Are we there yet? Expert Rev. Vaccines 2007, 6, 431-440.
60. Curtiss, R., III. Bacterial infectious disease control by vaccine development. J. Clin. Invest. 2002, 110, 1061-1066.
61. Byrd, C.M.; Bolken, T.C.; Jones, K.F.; Warren, T.K.; Vella, A.T.; McDonald, J.; King, D.; Blackwood, Z.; Hruby, D.E. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine 2002, 20, 2197-2205.
62. Chabalgoity, J.A.; Baz, A.; Rial, A.; Grille, S. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev. 2007, 18, 195-207.
63. Braat, H.; Rottiers, P.; Hommes, D.W.; Huyghebaert, N.; Remaut, E.; Remon, J.P.; van Deventer, S.J.; Neirynck, S.; Peppelenbosch, M.P.; Steidler, L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 2006, 4, 754-759.
64. Bruhn, K.W.; Craft, N.; Miller, J.F. Listeria as a vaccine vector. Microb. Infect. 2007, 9, 1226-1235.
65. Sztein, M.B.; Tanner, M.K.; Polotsky, Y.; Orenstein, J.M.; Levine, M.M. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella Typhi in humans. J. Immunol. 1995, 155, 3987-3993.
66. Sztein, M.B. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 2007, 45, S15-S19.
67. + T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J. Immunol. 2004, 173, 5852-5862.
68. Viret, J.F.; Favre, D.; Wegmuller, B.; Herzog, C.; Que, J.U.; Cryz, S.J., Jr.; Lang, A.B. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 1999, 67, 3680-3685.
69. Seegers, J.F.M.L. Lactobacilli as live vaccine delivery vectors: Progress and prospects. Trends Biotechnol. 2002, 20, 508-515.
70. Pontes, D.S.; de Azevedo, M.S.P.; Chatel, J.-M.; Langella, P.; Azevedo, V.; Miyoshi, A. Lactococcus lactis as a live vector: Heterologous protein production and DNA delivery systems. Protein Expr. Purif. 2011, 79, 165-175.
71. Marelli, B.; Perez, A.R.; Banchio, C.; de Mendoza, D.; Magni, C. Oral immunization with live Lactococcus lactis expressing rotavirus VP8* subunit induces specific immune response in mice. J. Virol. Methods 2011, 175, 28-37.
72. Mielcarek, N.; Alonso, S.; Locht, C. Nasal vaccination using live bacterial vectors. Adv. Drug Del. Rev. 2001, 51, 55-69.
73. Wilson, R.L.; Hruby, D.E. Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism. Adv. Drug Del. Rev. 2005, 57, 1392-1402.
74. Oggioni, M.R.; Manganelli, R.; Contorni, M.; Tommasino, M.; Pozzi, G. Immunization of mice by oral colonization with live recombinant commensal Streptococci. Vaccine 1995, 13, 775-779.
75. Johnson, P.V.; Blair, B.M.; Zeller, S.; Kotton, C.N.; Hohmann, E.L. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: Preclinical evaluation and oral inoculation of volunteers. Microbiol. Immunol. 2011, 55, 304-317.
76. Eypper, E.H.; Johnson, P.V.; Purro, E.I.; Hohmann, E.L. Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant. Vaccine 2013, 31, 3257-3261.
77. Ho, S.Y.; Chua, S.Q.; Foo, D.G.W.; Locht, C.; Chow, V.T.; Poh, C.L.; Alonso, S. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect. Immun. 2008, 76, 111-119.
78. Maciag, P.C.; Radulovic, S.; Rothman, J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27, 3975-3983.
79. Khan, S.; Chatfield, S.; Stratford, R.; Bedwell, J.; Bentley, M.; Sulsh, S.; Giemza, R.; Smith, S.; Bongard, E.; Cosgrove, C.A.; et al. Ability of SPI2 mutant of S. Typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine 2007, 25, 4175-4182.
80. Bumann, D.; Behre, C.; Behre, K.; Herz, S.; Gewecke, B.; Gessner, J.E.; von Specht, B.U.; Baumann, U. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2010, 28, 707-713.
81. Aebischer, T.; Bumann, D.; Epple, H.J.; Metzger, W.; Schneider, T.; Cherepnev, G.; Walduck, A.K.; Kunkel, D.; Moos, V.; Loddenkemper, C.; et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 2008, 57, 1065-1072.
82. Xu de, Q.; Cisar, J.O.; Osorio, M.; Wai, T.T.; Kopecko, D.J. Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: Preclinical evidence of immunogenicity and protection. Vaccine 2007, 25, 6167-6175.
83. Roland, K.L.; Cloninger, C.; Kochi, S.K.; Thomas, L.J.; Tinge, S.A.; Rouskey, C.; Killeen, K.P. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 2007, 25, 8574-8584.
84. Van, T.T.H.; Lin, Y.C.; Coloe, P.J.; Smooker, P.M. From animals to humans: Can vaccines make the transition? In Vaccinations: Procedures, Types and Controversy; Bezio, A.I., Campbell, B.E., Eds.; Nova Science Publishers:Hauppauge, NY, USA, 2012; pp. 1-63.
85. Kasinskas, R.W.; Forbes, N.S. Salmonella Typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 2007, 67, 3201-3209.
86. Baban, C.K.; Cronin, M.; O'Hanlon, D.; O'Sullivan, G.C.; Tangney, M. Bacteria as vectors for gene therapy of cancer. Bioeng. Bugs 2010, 1, 385-394.
87. Yu, Y.A.; Shabahang, S.; Timiryasova, T.M.; Zhang, Q.; Beltz, R.; Gentschev, I.; Goebel, W.; Szalay, A.A. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 2004, 22, 313-320.
88. Kerkar, S.P.; Restifo, N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012, 72, 3125-3130.
89. Sitkovsky, M.V.; Lukashev, D.; Apasov, S.; Kojima, H.; Koshiba, M.; Caldwell, C.; Ohta, A.; Thiel, M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 2004, 22, 657-682.
90. Schlosser, H.A.; Theurich, S.; Shimabukuro-Vornhagen, A.; Holtick, U.; Stippel, D.L.; von Bergwelt-Baildon, M. Overcoming tumor-mediated immunosuppression. Immunotherapy 2014, 6, 973-988.
91. Leschner, S.; Weiss, S. Salmonella-allies in the fight against cancer. J. Mol. Med. (Berl.) 2010, 88, 763-773.
92. Möse, J.R.; Möse, G. Oncolysis by Clostridia. I. activity of Clostridium Butyricum (M-55) and other nonpathogenic clostridia against the ehrlich carcinoma. Cancer Res. 1964, 24, 212-216.
93. Luo, X.; Li, Z.; Lin, S.; Le, T.; Ittensohn, M.; Bermudes, D.; Runyab, J.D.; Shen, S.Y.; Chen, J.; King, I.C.; et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol. Res. 2001, 12, 501-508.
94. Zhao, M.; Yang, M.; Li, X.-M.; Jiang, P.; Baranov, E.; Li, S.; Xu, M.; Penman, S.; Hoffman, R.M. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella Typhimurium. Proc. Natl. Acad. Sci. USA 2005, 102, 755-760.
95. Mengesha, A.; Wei, J.Z.; Zhou, S.F.; Wei, M.Q. Clostridial spores to treat solid tumours-potential for a new therapeutic modality. Curr. Gene Ther. 2010, 10, 15-26.
96. Umer, B.; Good, D.; Ann, J.; Duan, W.; Wei, M.Q. Clostridial spores for cancer therapy: Targeting solid tumour microenvironment. J. Toxicol. 2012, doi:10.1155/2012/862764.
97. Zuo, S.G.; Chen, Y.; Wu, Z.P.; Liu, X.; Liu, C.; Zhou, Y.C.; Wu, C.L.; Jin, C.G.; Gu, Y.L.; Li, J.; et al. Orally administered DNA vaccine delivery by attenuated Salmonella Typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol. Pharm. Bull. 2010, 33, 174-182.
98. + breast tumors in a mouse model. J. Immunol. 2009, 182, 5537-5546.
99. Li, C.; Chen, X.; Kou, L.; Hu, B.; Zhu, L.P.; Fan, Y.R.; Wu, Z.W.; Wang, J.J.; Xu, G.X. Selenium-Bifidobacterium longum as a delivery system of endostatin for inhibition of pathogenic bacteria and selective regression of solid tumor. Exp. Ther. Med. 2010, 1, 129-135.
100. Li, X.; Fu, G.F.; Fan, Y.R.; Liu, W.H.; Liu, X.J.; Wang, J.J.; Xu, G.X. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 2003, 10, 105-111.
101. Yin, Y.A.N.; Kou, L.E.I.; Wang, J.-J.; Xu, G.-X. Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice. Exp. Ther. Med. 2012, 3, 481-486.
102. Xu, Y.F.; Zhu, L.P.; Hu, B.; Fu, G.F.; Zhang, H.Y.; Wang, J.J.; Xu, G.X. A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 2007, 14, 151-157.
103. Lee, C.H.; Wu, C.L.; Shiau, A.L. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J. Gene Med. 2004, 6, 1382-1393.
104. Yang, N.; Zhu, X.; Chen, L.; Li, S.; Ren, D. Oral administration of attenuated S. Typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biol. Ther. 2008, 7, 145-151.
105. Jiang, Z.; Zhao, P.; Zhou, Z.; Liu, J.; Qin, L.; Wang, H. Using attenuated Salmonella Typhi as tumor targeting vector for MDR1 siRNA delivery. Cancer Biol. Ther. 2007, 6, 555-560.
106. Loeffler, M.; Le'Negrate, G.; Krajewska, M.; Reed, J.C. Inhibition of tumor growth using Salmonella expressing Fas Ligand. J. Natl. Cancer Inst. 2008, 100, 1113-1116.
107. Ryan, R.M.; Green, J.; Williams, P.J.; Tazzyman, S.; Hunt, S.; Harmey, J.H.; Kehoe, S.C.; Lewis, C.E. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther. 2009, 16, 329-339.
108. Ganai, S.; Arenas, R.B.; Forbes, N.S. Tumour-targeted delivery of TRAIL using Salmonella Typhimurium enhances breast cancer survival in mice. Br. J. Cancer 2009, 101, 1683-1691.
109. Chen, J.; Yang, B.; Cheng, X.; Qiao, Y.; Tang, B.; Chen, G.; Wei, J.; Liu, X.; Cheng, W.; Du, P.; et al. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model. Cancer Sci. 2012, 103, 325-333.
110. Guan, G.F.; Zhao, M.; Liu, L.M.; Jin, C.S.; Sun, K.; Zhang, D.J.; Yu, D.J.; Cao, H.W.; Lu, Y.Q.; Wen, L.J. Salmonella Typhimurium mediated delivery of Apoptin in human laryngeal cancer. Int. J. Med. Sci. 2013, 10, 1639-1648.
111. Zeng, S.; Zhang, J.; Zhang, J.; Liu, Q.; Wang, S.; Wu, S.; Peng, X.; Shao, J.; Huang, W. Suppression of murine melanoma growth by a vaccine of attenuated Salmonella carrying heat shock protein 70 and Herpes simplex virus-thymidine kinase genes. Oncol. Rep. 2012, 27, 798-806.
112. Pawelek, J.M.; Low, K.B.; Bermudes, D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997, 57, 4537-4544.
113. Tang, W.; He, Y.; Zhou, S.; Ma, Y.; Liu, G. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J. Exp. Clin. Cancer Res. 2009, 28, 155.
114. Palffy, R.; Gardlik, R.; Hodosy, J.; Behuliak, M.; Resko, P.; Radvansky, J.; Celec, P. Bacteria in gene therapy: Bactofection versus alternative gene therapy. Gene Ther. 2005, 13, 101-105.
115. Abdul-Wahid, A.; Faubert, G. Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella Typhimurium bactofection vehicle. Vaccine 2007, 25, 8372-8383.
116. Fu, W.; Lan, H.; Li, S.; Han, X.; Gao, T.; Ren, D. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors. Cancer Gene Ther. 2008, 15, 474-484.
117. Lee, C.H.; Wu, C.L.; Shiau, A.L. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther. 2005, 12, 175-184.
118. Sizemore, D.R.; Branstrom, A.A.; Sadoff, J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995, 270, 299-302.
119. Dietrich, G.; Bubert, A.; Gentschev, I.; Sokolovic, Z.; Simm, A.; Catic, A.; Kaufmann, S.H.; Hess, J.; Szalay, A.A.; Goebel, W. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 1998, 16, 181-185.
120. Buttaro, C.; Fruehauf, J.H. Engineered E. coli as vehicles for targeted therapeutics. Curr. Gene Ther. 2010, 10, 27-33.
121. Friedlos, F.; Lehouritis, P.; Ogilvie, L.; Hedley, D.; Davies, L.; Bermudes, D.; King, I.; Martin, J.; Marais, R.; Springer, C.J. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin. Cancer Res. 2008, 14, 4259-4266.
122. Loessner, H.; Weiss, S. Bacteria-mediated DNA transfer in gene therapy and vaccination. Expert Opin. Biol. Ther. 2004, 4, 157-168.
123. Sasaki, T.; Fujimori, M.; Hamaji, Y.; Hama, Y.; Ito, K.; Amano, J.; Taniguchi, S. Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci. 2006, 97, 649-657.
124. Yazawa, K.; Fujimori, M.; Nakamura, T.; Sasaki, T.; Amano, J.; Kano, Y.; Taniguchi, S. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res. Treat. 2001, 66, 165-170.
125. Zhu, L.P.; Yin, Y.; Xing, J.; Li, C.; Kou, L.; Hu, B.; Wu, Z.W.; Wang, J.J.; Xu, G.X. Therapeutic efficacy of Bifidobacterium longum-mediated human granulocyte colony-stimulating factor and/or endostatin combined with cyclophosphamide in mouse-transplanted tumors. Cancer Sci. 2009, 100, 1986-1990.
126. Howarth, J.L.; Lee, Y.B.; Uney, J.B. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol. Toxicol. 2010, 26, 1-20.
127. Al-Dosari, M.S.; Gao, X. Nonviral gene delivery: Principle, limitations, and recent progress. AAPS J. 2009, 11, 671-681.
128. Schoen, C.; Kolb-Maurer, A.; Geginat, G.; Loffler, D.; Bergmann, B.; Stritzker, J.; Szalay, A.A.; Pilgrim, S.; Goebel, W. Bacterial delivery of functional messenger RNA to mammalian cells. Cell Microbiol. 2005, 7, 709-724.
129. Southwick, F.S.; Purich, D.L. Listeria and Shigella actin-based motility in host cells. Trans. Am. Clin. Climatol. Assoc. 1998, 109, 160-173.
130. Tilney, L.G.; Portnoy, D.A. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J. Cell Biol. 1989, 109, 1597-1608.
131. Darji, A.; zur Lage, S.; Garbe, A.I.; Chakraborty, T.; Weiss, S. Oral delivery of DNA vaccines using attenuated Salmonella Typhimurium as carrier. FEMS Immunol. Med. Microbiol. 2000, 27, 341-349.
132. Paterson, Y.; Guirnalda, P.D.; Wood, L.M. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin. Immunol. 2010, 22, 183-189.
133. Wallecha, A.; Carroll, K.D.; Maciag, P.C.; Rivera, S.; Shahabi, V.; Paterson, Y. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv. Appl. Microbiol. 2009, 66, 1-27.
134. + T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection. Cancer Res. 2009, 69, 4327-4334.
135. Gardlik, R.; Behuliak, M.; Palffy, R.; Celec, P.; Li, C.J. Gene therapy for cancer: Bacteria-mediated anti-angiogenesis therapy. Gene Ther. 2011, 18, 425-431.
136. Jia, L.J.; Xu, H.M.; Ma, D.Y.; Hu, Q.G.; Huang, X.F.; Jiang, W.H.; Li, S.F.; Jia, K.Z.; Huang, Q.L.; Hua, Z.C. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol. Ther. 2005, 4, 840-845.
137. Fu, G.F.; Li, X.; Hou, Y.Y.; Fan, Y.R.; Liu, W.H.; Xu, G.X. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 2005, 12, 133-140.
138. Hu, B.; Kou, L.; Li, C.; Zhu, L.P.; Fan, Y.R.; Wu, Z.W.; Wang, J.J.; Xu, G.X. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther. 2009, 16, 655-663.
139. Wang, J.; Lu, Z.; Wientjes, M.G.; Au, J.L.S. Delivery of siRNA therapeutics: Barriers and carriers. AAPS J. 2010, 12, 492-503.
140. Khatri, N.I.; Rathi, M.N.; Baradia, D.P.; Trehan, S.; Misra, A. in vivo delivery aspects of miRNA, shRNA and siRNA. Crit. Rev. Ther. Drug Carrier Syst. 2012, 29, 487-527.
141. Lage, H.; Kruhn, A. Bacterial delivery of RNAi effectors: Transkingdom RNAi. J. Vis. Exp. 2010, doi:10.3791/2099.
142. Lu, P.Y.; Xie, F.; Woodle, M.C. In vivo application of RNA interference: From functional genomics to therapeutics. Adv. Genet. 2005, 54, 117-142.
143. Xiang, S.; Keates, A.C.; Fruehauf, J.; Yang, Y.; Guo, H.; Nguyen, T.; Li, C.J. In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi). Methods Mol. Biol. 2009, 487, 147-160.
144. Zhao, H.F.; L'Abbe, D.; Jolicoeur, N.; Wu, M.; Li, Z.; Yu, Z.; Shen, S.H. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat. Methods 2005, 2, 967-973.
145. Xiang, S.; Fruehauf, J.; Li, C.J. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat. Biotechnol. 2006, 24, 697-702.
146. Morin, P.J. beta-Catenin signaling and cancer. Bioessays 1999, 21, 1021-1030.
147. Zhang, L.; Gao, L.; Zhao, L.; Guo, B.; Ji, K.; Tian, Y.; Wang, J.; Yu, H.; Hu, J.; Kalvakolanu, D. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar Typhimurium carrying plasmid-based small interfering RNAs. Cancer Res. 2007, 67, 5859-5864.
148. Blache, C.A.; Manuel, E.R.; Kaltcheva, T.I.; Wong, A.N.; Ellenhorn, J.D.; Blazar, B.R.; Diamond, D.J. Systemic delivery of Salmonella Typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res. 2012, 72, 6447-6456.
149. Thorburn, A. Death receptor-induced cell killing. Cell. Signal. 2004, 16, 139-144.
150. Backendorf, C.; Noteborn, M.H. Apoptin towards safe and efficient anticancer therapies. Adv. Exp. Med. Biol. 2014, 818, 39-59.
151. Weyel, D.; Sedlacek, H.H.; Muller, R.; Brusselbach, S. Secreted human beta-glucuronidase: A novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 2000, 7, 224-231.
152. Springer, C.J.; Niculescu-Duvaz, I. Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 2000, 105, 1161-1167.
153. Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 1986, 46, 5276-5281.
154. Fox, M.E.; Lemmon, M.J.; Mauchline, M.L.; Davis, T.O.; Giaccia, A.J.; Minton, N.P.; Brown, J.M. Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther. 1996, 3, 173-178.
155. Nuyts, S.; Theys, J.; Landuyt, W.; van Mellaert, L.; Lambin, P.; Anne, J. Increasing specificity of anti-tumor therapy: Cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res. 2001, 21, 857-861.
156. Nakamura, T.; Sasaki, T.; Fujimori, M.; Yazawa, K.; Kano, Y.; Amano, J.; Taniguchi, S. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem. 2002, 66, 2362-2366.
157. Mei, S.; Theys, J.; Landuyt, W.; Anne, J.; Lambin, P. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella Typhimurium. Anticancer Res. 2002, 22, 3261-3266.
158. Theys, J.; Pennington, O.; Dubois, L.; Anlezark, G.; Vaughan, T.; Mengesha, A.; Landuyt, W.; Anné, J.; Burke, P.J.; Dûrre, P.; et al. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br. J. Cancer 2006, 95, 1212-1219.
159. Lemmon, M.J.; van Zijl, P.; Fox, M.E.; Mauchline, M.L.; Giaccia, A.J.; Minton, N.P.; Brown, J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997, 4, 791-796.
160. Fu, W.; Lan, H.; Liang, S.; Gao, T.; Ren, D. Suicide gene/prodrug therapy using Salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 2'-deoxyriboside in murine mammary carcinoma 4T1 model. Cancer Sci. 2008, 99, 1172-1179.
161. Nemunaitis, J.; Cunningham, C.; Senzer, N.; Kuhn, J.; Cramm, J.; Litz, C.; Cavagnolo, R.; Cahill, A.; Clairmont, C.; Sznol, M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003, 10, 737-744.
162. Borrello, I.; Pardoll, D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev. 2002, 13, 185-193.
163. O'Connell, L.; O'Sullivan, G.C.; Collins, J.K.; Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184, 1075-1082.
164. Shevach, E.M. CD4+CD25+ suppressor T cells: More questions than answers. Nat. Rev. Immunol. 2002, 2, 389-400.
165. Bui, J.D.; Schreiber, R.D. Cancer immunosurveillance, immunoediting and inflammation: Independent or interdependent processes? Curr. Opin. Immunol. 2007, 19, 203-208.
166. Loeffler, M.; Le'Negrate, G.; Krajewska, M.; Reed, J.C. Salmonella Typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol. Immunother. 2009, 58, 769-775.
167. Yoon, W.S.; Chae, Y.S.; Hong, J.; Park, Y.K. Antitumor therapeutic effects of a genetically engineered Salmonella Typhimurium harboring TNF-alpha in mice. Appl. Microbiol. Biotechnol. 2011, 89, 1807-1819.
168. Loeffler, M.; Le'Negrate, G.; Krajewska, M.; Reed, J.C. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther. 2008, 15, 787-794.
169. al-Ramadi, B.K.; Fernandez-Cabezudo, M.J.; El-Hasasna, H.; Al-Salam, S.; Bashir, G.; Chouaib, S. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin. Immunol. 2009, 130, 89-97.
170. Loeffler, M.; Le'Negrate, G.; Krajewska, M.; Reed, J.C. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc. Natl. Acad. Sci. USA 2007, 104, 12879-12883.
171. Agorio, C.; Schreiber, F.; Sheppard, M.; Mastroeni, P.; Fernandez, M.; Martinez, M.A.; Chabalgoity, J.A. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J. Gene Med. 2007, 9, 416-423.
172. Lu, B.; Finn, O.J. T-cell death and cancer immune tolerance. Cell Death Differ. 2007, 15, 70-79.
173. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 2003, 21, 807-839.
174. Hobohm, U.; Stanford, J.L.; Grange, J.M. Pathogen-associated molecular pattern in cancer immunotherapy. Crit. Rev. Immunol. 2008, 28, 95-107.
175. Singh, R.; Wallecha, A. Cancer immunotherapy using recombinant Listeria monocytogenes: Transition from bench to clinic. Hum. Vaccines 2011, 7, 497-505.
176. Hernandez-Luna, M.A.; Luria-Perez, R.; Huerta-Yepez, S. Therapeutic intervention alternatives in cancer, using attenuated live bacterial vectors: Salmonella enterica as a carrier of heterologous molecules. Rev. Invest. Clin. 2013, 65, 65-73.
177. Wood, L.M.; Guirnalda, P.D.; Seavey, M.M.; Paterson, Y. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol. Res. 2008, 42, 233-245.
178. Seavey, M.M.; Pan, Z.K.; Maciag, P.C.; Wallecha, A.; Rivera, S.; Paterson, Y.; Shahabi, V. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin. Cancer Res. 2009, 15, 924-932.
179. Shahabi, V.; Seavey, M.M.; Maciag, P.C.; Rivera, S.; Wallecha, A. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2011, 18, 53-62.
180. Gunn, G.R.; Zubair, A.; Peters, C.; Pan, Z.K.; Wu, T.C.; Paterson, Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 2001, 167, 6471-6479.
181. Sewell, D.A.; Pan, Z.K.; Paterson, Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008, 26, 5315-5320.
182. Sewell, D.A.; Shahabi, V.; Gunn, G.R., 3rd; Pan, Z.K.; Dominiecki, M.E.; Paterson, Y. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 2004, 64, 8821-8825.
183. Maciag, P.C.; Seavey, M.M.; Pan, Z.K.; Ferrone, S.; Paterson, Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008, 68, 8066-8075.
184. Wallecha, A.; Maciag, P.C.; Rivera, S.; Paterson, Y.; Shahabi, V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin. Vaccine Immunol. 2009, 16, 96-103.
185. Yang, Y.; Hou, J.; Lin, Z.; Zhuo, H.; Chen, D.; Zhang, X.; Chen, Y.; Sun, B. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell. Mol. Immunol. 2014, 11, 184-196.
186. Overdevest, J.B.; Knubel, K.H.; Duex, J.E.; Thomas, S.; Nitz, M.D.; Harding, M.A.; Smith, S.C.; Frierson, H.F.; Conaway, M.; Theodorescu, D. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc. Natl. Acad. Sci. USA 2012, 109, E3588-E3596.
187. Senner, V.; Sturm, A.; Baur, I.; Schrell, U.H.; Distel, L.; Paulus, W. CD24 promotes invasion of glioma cells in vivo. J. Neuropathol. Exp. Neurol. 1999, 58, 795-802.
188. Baumann, P.; Cremers, N.; Kroese, F.; Orend, G.; Chiquet-Ehrismann, R.; Uede, T.; Yagita, H.; Sleeman, J.P. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005, 65, 10783-10793.
189. Cummins, J.; Tangney, M. Bacteria and tumours: Causative agents or opportunistic inhabitants? Infect. Agent. Cancer 2013, doi:10.1186/1750-9378-8-11.
190. Panteli, J.T.; Forkus, B.A.; Van Dessel, N.; Forbes, N.S. Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr. Biol. (Camb.) 2015, 7, 423-434.
191. Xiong, T.; Li, Y.; Li, Z.; Xie, X.; Lu, L. In vivo monitoring the process of tumor growth, metastasis and bacterial infection expressing GFP via real-time optical imaging. J. Biomed. Nanotechnol. 2013, 9, 274-280.
192. Cronin, M.; Akin, A.R.; Collins, S.A.; Meganck, J.; Kim, J.-B.; Baban, C.K.; Joyce, S.A.; van Dam, G.M.; Zhang, N.; van Sinderen, D.; et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS ONE 2012, 7, e30940.
193. Riedel, C.U.; Monk, I.R.; Casey, P.G.; Morrissey, D.; O'Sullivan, G.C.; Tangney, M.; Hill, C.; Gahan, C.G.M. Improved Luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl. Environ. Microbiol. 2007, 73, 3091-3094.
194. Tjuvajev, J.G.; Avril, N.; Oku, T.; Sasajima, T.; Miyagawa, T.; Joshi, R.; Safer, M.; Beattie, B.; DiResta, G.; Daghighian, F.; et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998, 58, 4333-4341.
195. Brader, P.; Stritzker, J.; Riedl, C.C.; Zanzonico, P.; Cai, S.; Burnazi, E.M.; Ghani, E.R.; Hricak, H.; Szalay, A.A.; Fong, Y.; et al. Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin. Cancer Res. 2008, 14, 2295-2302.
196. Soghomonyan, S.A.; Doubrovin, M.; Pike, J.; Luo, X.; Ittensohn, M.; Runyan, J.D.; Balatoni, J.; Finn, R.; Tjuvajev, J.G.; Blasberg, R.; et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 2005, 12, 101-108.
197. Tjuvajev, J.; Blasberg, R.; Luo, X.; Zheng, L.M.; King, I.; Bermudes, D. Salmonella-based tumor-targeted cancer therapy: Tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J. Control. Release 2001, 74, 313-315.